These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 23810938)
1. New paradigm for drug developments--from emerging market statistical perspective. Quan H; Chen X; Zhang J; Zhao PL Contemp Clin Trials; 2013 Nov; 36(2):697-703. PubMed ID: 23810938 [TBL] [Abstract][Full Text] [Related]
2. Consistency assessment with global and bridging development strategies in emerging markets. Li G; Chen J; Quan H; Shentu Y Contemp Clin Trials; 2013 Nov; 36(2):687-96. PubMed ID: 23702264 [TBL] [Abstract][Full Text] [Related]
3. [Contact and dialogue between drug companies and the global regulatory authorities throughout research and development phase]. Kock M; Thomsen MK Ugeskr Laeger; 2003 Apr; 165(16):1649-52. PubMed ID: 12756820 [TBL] [Abstract][Full Text] [Related]
4. An industry statistician's perspective on PHC drug development. Fridlyand J; Yeh RF; Mackey H; Bengtsson T; Delmar P; Spaniolo G; Lieberman G Contemp Clin Trials; 2013 Nov; 36(2):624-35. PubMed ID: 23648396 [TBL] [Abstract][Full Text] [Related]
5. Challenges in the clinical development requirements for the marketing authorization of new medicines in southeast Asia. Kudrin A J Clin Pharmacol; 2009 Mar; 49(3):268-80. PubMed ID: 19168433 [TBL] [Abstract][Full Text] [Related]
6. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category. Glasziou PP Med J Aust; 1995 Jan; 162(1):33-6. PubMed ID: 7605432 [TBL] [Abstract][Full Text] [Related]
7. Closing the drug lag for new drug submission and review in Japan: An industry perspective. Poirier AF Clin Pharmacol Ther; 2015 Nov; 98(5):486-8. PubMed ID: 26239646 [TBL] [Abstract][Full Text] [Related]
8. United States of America Department of Health and Human Services support for advancing influenza vaccine manufacturing in the developing world. Perdue ML; Bright RA Vaccine; 2011 Jul; 29 Suppl 1():A48-50. PubMed ID: 21684430 [TBL] [Abstract][Full Text] [Related]
9. Clinical trials in "emerging markets": regulatory considerations and other factors. Singh R; Wang O Contemp Clin Trials; 2013 Nov; 36(2):711-8. PubMed ID: 24070788 [TBL] [Abstract][Full Text] [Related]
10. [An analysis of the pharmaceuticals market in Vietnam]. Simonet D Sante; 2001; 11(3):155-60. PubMed ID: 11641078 [TBL] [Abstract][Full Text] [Related]
11. Brazil: An emerging partner in drug R&D. Rodrigues DG IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884 [TBL] [Abstract][Full Text] [Related]
12. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
13. New ways of insulin delivery. Heinemann L Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811 [TBL] [Abstract][Full Text] [Related]
14. Clinical trials in the new millennium. DeMets DL Stat Med; 2002 Oct; 21(19):2779-87. PubMed ID: 12325093 [TBL] [Abstract][Full Text] [Related]
15. Regulatory constraints as seen from the pharmaceutical industry. Galligani G; David-Andersen I; Fossum B Dev Biol (Basel); 2005; 121():235-41. PubMed ID: 15962486 [TBL] [Abstract][Full Text] [Related]
16. Emerging trends in contract research industry in India. Drabu S; Gupta A; Bhadauria A Contemp Clin Trials; 2010 Sep; 31(5):419-22. PubMed ID: 20609394 [TBL] [Abstract][Full Text] [Related]
17. Economics of new oncology drug development. DiMasi JA; Grabowski HG J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942 [TBL] [Abstract][Full Text] [Related]
18. Drug development in oncology: a regulatory perspective. Augustus S Am J Ther; 2011 Jul; 18(4):323-31. PubMed ID: 20335790 [TBL] [Abstract][Full Text] [Related]
19. FDA draft guidance on adaptive design clinical trials: Pfizer's perspective. Chuang-Stein C; Beltangady M J Biopharm Stat; 2010 Nov; 20(6):1143-9. PubMed ID: 21058110 [TBL] [Abstract][Full Text] [Related]
20. Alcohol medications development: advantages and caveats of government/academia collaborating with the pharmaceutical industry. Litten RZ; Ryan M; Falk D; Fertig J Alcohol Clin Exp Res; 2014 May; 38(5):1196-9. PubMed ID: 24689461 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]